August 3, 2018 – By Glen Chin
Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.11 EPS on August, 14.They anticipate $0.08 EPS change or 42.11% from last quarter’s $-0.19 EPS. After having $-0.19 EPS previously, ChemoCentryx, Inc.’s analysts see -42.11% EPS growth. The stock increased 0.36% or $0.04 during the last trading session, reaching $11.21. About 89,716 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since August 3, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 ChemoCentryx 4Q EPS 80c
Managed Asset Portfolios Llc increased Orange (ORAN) stake by 2.73% reported in 2018Q1 SEC filing. Managed Asset Portfolios Llc acquired 24,705 shares as Orange (ORAN)’s stock declined 0.17%. The Managed Asset Portfolios Llc holds 928,032 shares with $15.85 million value, up from 903,327 last quarter. Orange now has $44.37B valuation. The stock decreased 0.94% or $0.16 during the last trading session, reaching $16.91. About 380,909 shares traded or 49.71% up from the average. Orange S.A. (NYSE:ORAN) has declined 1.02% since August 3, 2017 and is downtrending. It has underperformed by 13.59% the S&P500. Some Historical ORAN News: 26/04/2018 – Orange Backs 2018 View; 13/03/2018 – GUIDANCE: Orange Exp EU750m 10Y MS +37 Area +/-2; 12/04/2018 – Press release : Orange Belgium will publish its results for the first quarter of 2018 on Friday, April 20 at 07:00 CET; 05/03/2018 – Orange Shuffles, Expands Its Executive Committee; 16/05/2018 – ORANGE EXPECTS IVORY COAST NETWORK FULLY RESTORED BY MAY 20; 14/05/2018 – TM Forum Catalyst: Prodapt Partners With Orange, awareX, re:infer, incognito and Blue Prism to Enhance Orange’s Livebox Return; 09/05/2018 – BRAZIL ’18-19 ORANGE CROP SEEN FALLING 27.6% Y/Y: FUNDECITRUS; 05/04/2018 – Orange Closes Above 50-Day Moving Average: Technicals; 05/03/2018 DiscoverReady Named a Relativity Orange-Level Best in Service Provider; 09/04/2018 – Woodward: L’Orange to Be Renamed Woodward L’Orange, Be Integrated in Company’s Industrial Segment
Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It dropped, as 10 investors sold ChemoCentryx, Inc. shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. 62,600 are held by Spark Inv Mgmt Limited Liability. Panagora Asset Mngmt holds 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 369,959 shares. Manufacturers Life Ins The reported 20,352 shares or 0% of all its holdings. Daiwa Secs Grp Inc holds 0% or 269 shares. Bogle Investment L P De owns 21,104 shares or 0.02% of their US portfolio. Blackrock Inc holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 2.57M shares. The France-based Carmignac Gestion has invested 0.04% in ChemoCentryx, Inc. (NASDAQ:CCXI). State Bank Of Montreal Can has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Arrowstreet Partnership has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Legal & General Group Public Ltd, a United Kingdom-based fund reported 4,583 shares. Fny Managed Accounts Ltd Liability Corp invested in 0% or 205 shares. Federated Pa reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Pub Employees Retirement Sys Of Ohio has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Credit Suisse Ag reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Citigroup has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 3,315 shares.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since March 13, 2018 according to SRatingsIntel. The company was maintained on Tuesday, March 13 by JP Morgan.
Another recent and important ChemoCentryx, Inc. (NASDAQ:CCXI) news was published by Nasdaq.com which published an article titled: “ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018” on August 02, 2018.
Since May 1, 2018, it had 0 buys, and 12 selling transactions for $7.89 million activity. 50,000 shares were sold by Schall Thomas J., worth $550,858. KANAYA SUSAN M sold $15,709 worth of stock or 1,366 shares. 25,179 ChemoCentryx, Inc. (NASDAQ:CCXI) shares with value of $344,201 were sold by Cappel Markus J..
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.